The pharmaceutical company Gossamer Bio, celebrates a significant achievement with the publication of its TORREY Phase 2 study results in the esteemed Lancet Respiratory Medicine journal. The study, titled “Seralutinib in Adults with Pulmonary Arterial Hypertension (TORREY),” highlights promising advancements in treating pulmonary hypertension (PH).

TORREY, a Phase 2 clinical trial, evaluated the efficacy and safety of Gossamer’s novel therapy, seralutinib, in PAH patients. The results, published in Lancet Respiratory Medicine, demonstrated a notable improvement in key health markers compared to the placebo group. Following this success, seralutinib has progressed into the Phase 3 PROSERA Study, aiming to further validate its potential in improving patients’ lives.

Faheem Hasnain, CEO of Gossamer Bio, expressed optimism about the study’s implications, stating, “The publication of TORREY results in Lancet Respiratory Medicine marks a significant step in our mission to address unmet medical needs in pulmonary hypertension. These findings fuel our enthusiasm for seralutinib’s potential in transforming patient care.”

For more information about Gossamer Bio and its groundbreaking research, please visit Gossamer Bio’s website.